Phase 1 Study of Ceritinib Combined With Trametinib in Patients With Advanced ALK- or ROS1-Positive NSCLC by Matthew S. Lara, BS, Matthew A. Gubens, MD, Bianca Bacaltos, MS, Lea Daran, BA, Steffany L. Lim, BS, Tianhong Li, MD, David R. Gandara, MD, Trever G. Bivona, MD, PhD, Jonathan W. Riess, MD, Collin M. Blakely, MD, PhD

Get full text

S1701, A Randomized Phase 2 Trial of Carboplatin-Paclitaxel With and Without Ramucirumab in Patients With Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma by Anne S. Tsao, MD, MBA, Ming-Hui Hsieh, MS, Marianna Koczywas, MD, Janet Tu, MD, Jonathan Riess, MD, MS, Tawee Tanvetyanon, MD, Barbara T. Ma, MD, Ying-Qi Zhao, PhD, Mary W. Redman, PhD, Martin J. Edelman, MD, David R. Gandara, MD, Jhanelle E. Gray, MD, Karen L. Kelly, MD

Get full text

Immune Cell Dynamics in EGFR-Mutated NSCLC Treated With Afatinib and Pembrolizumab: Results From a Phase IB Study by Jonathan W. Riess, MD, Matthew S. Lara, BS, Miguel Lopez de Rodas, MD, Guillaume Luxardi, PhD, Samantha Herbert, MSPH, Michiko Shimoda, PhD, Karen Kelly, MD, Alexander Meerlev, PhD, Elizabeth Moore, MD, Laurel Beckett, PhD, Arta Monjazeb, MD, PhD, Kurt Schalper, MD, PhD, Emanual Maverakis, MD, David R. Gandara, MD

Get full text